Pharma IQ Members


Gerald Clarke
79 results
of 8
Medical devices are undergoing a technical transformation in terms of software, interconnectivity and interoperability. This increase of function comes with an increase in risk from cybersecurity threats which puts not only the patients with medical devices potentially at risk, but has wider implications for connected digital infrastructure too....Full Article »
Spring cleaning, partnerships and optimism our editor asks is this Spring in the air? Pharma restructuring continues unabated and the latest deals to be announced are some of the biggest yet. GSK and Novartis will be swapping business units in multibillion dollar deals and other, bigger deals on the horizon may reach $100 billion....Full Article »
TED talks have grown a huge reputation for inspirational in innovative talks in recent years and now register millions of views every day. This Monday, our editor attended the TEDMED conference at the Albert Hall ‘Imagining the Future of Medicine.' Read this article to discover the two talks which could represent significant healthcare...Full Article »
The patents on a majority of the top-selling biologic drugs currently on the market will have expired by 2020, an amount which may be equivalent to $67 billion. Can we expect then a rush of biosimilar products to the market, drastically lowering spend on biological drugs?...Full Article »
The informatics landscape is changing quickly and innovation could be the key to increasing efficiency. Jeff Hurst, Senior Scientist at the Hershey's Company talks us through these changes and how the industry is moving away from robots towards more innovative methods including mobile apps. He also talks about the dangers of...Full Article »
With, the NHS’ new health information database, lives could be saved or endangered depending on how well the service is implemented. If the early handling of the project is an indication of the quality, it does not bode well. What can save this important project?...Full Article »
Our editor attended the PharmaTimes' meeting on PPRS and spoke with those who were there. Read the 5 key things he learned at the meeting...Full Article »
The pharma industry has a lot to learn from the food and beverage industry when it comes to contract manufacturing. To get to grips with this outsider's view, we spoke with Steve Hills, European Contract Manufacturing Director at Pepsico. Steve outlines where companies can go wrong in working with CMOs...Full Article »
A new report suggests the HTS market is to hit $19 billion by 2018. Our editor looks at the drivers behind the growth and has a look at a potential future in silico method of HTS which may one day give it a run for its money....Full Article »
Where can companies go wrong in their relationship with a CMO and what have been the major changes in these relationships in recent years? We spoke with Jim Browne, former Director of External Supply at GlaxoSmithKline and currently Director at JTB Consultancy Ltd to find out the answers to these questions. Jim also talks about they key to...Full Article »
79 results
of 8